Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SJP002 in Patients With Dry Eye Syndrome
NCT03723811Phase 2Completed
- Sponsor
- Samjin Pharmaceutical Co., Ltd.
- Start
- Nov 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SJP002 in dry eye syndrome (DED) (4 arms), sponsored by Samjin Pharmaceutical Co., Ltd. Primary endpoint: Fluorescein Corneal Staining at 4 weeks. Started Nov 2017; status: completed.
02
Drugs
SJP002
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT03723811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03723811.